Abstracts tagged "Osteoarthritis"

Abstract Number: 1801 • ACR Convergence 2025
Matrikine Activation of Synovial Fibroblasts Promotes Monocyte Migration and Stimulates an OA Chondrocyte Phenotype
Richard Loeser¹, Jorge Fernandez Davila¹, Philip Coryell², Susan Chubinskaya³ and Doug Phanstiel⁴, ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina-Chapel Hill, Chapel Hill, NC, ³University of Texas Medical Branch, Galveston, TX, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Protease cleavage of matrix proteins generates matrix fragments including fibronectin fragments (FN-f) found in OA cartilage and synovial fluid. Matrix fragments or “matrikines” activate…
Abstract Number: 2082 • ACR Convergence 2025
Pharmacokinetic Profile of MM-II Following a Single Intra-Articular Injection in Patients with Knee Osteoarthritis in a Phase 2b Randomized, Controlled, Dose-Ranging Trial
Thomas Schnitzer¹, Xavier Chevalier², Helene Rovsing³, Edith Lau⁴, Sidsel Boll⁵, Ballari Brahmachari⁶, Richard Chou⁷, Tarini Joshi⁸, Roni Wechsler⁹, Sveta Weiner¹⁰, Mudgal Kothekar¹¹, Asger Bihlet¹² and Philip Conaghan¹³, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Henri Mondor Hospital, University Paris XII UPEC, Créteil, France, ³Sanos Clinic, Gandrup, Denmark, ⁴Hong Kong Center for Clinical Research, Hong Kong, Hong Kong, ⁵Sanos Clinic, Vejle, Denmark, ⁶Sun Pharmaceuticals Industries Ltd., mumbai, Maharashtra, India, ⁷Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁸Sun Pharmaceutical Industries Limited, Mumbai, India, ⁹Moebius Medical, Tel Aviv, Israel, ¹⁰Sun Pharma Advanced Research Company Limited, Princeton, NJ, ¹¹Sun Pharma Advanced Research Company Limited, Andheri (E), Princeton, NJ, ¹²NBCD A/S, Herlev, Denmark, ¹³University of Leeds, Leeds, United Kingdom
Background/Purpose: MM-II is a first-in-class investigational treatment for knee OA pain that consists of a one-time IA injection of empty liposomes comprised of phospholipids dipalmitoylphosphatidylcholine…
Abstract Number: 2098 • ACR Convergence 2025
Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial
Natalie Keller¹, Bryant England², Katherine Wysham³, Mercedes Quinones⁴, Marianna Olave⁵, Sarah Wetzel⁶, Hannah Brubeck⁷, Rachel Gillcrist⁶, Criswell Lavery⁸, Bibiana Ateh⁹, Bridget Kramer², Kimberly Hayes⁶, Rui Xiao⁸, Kaitian Jin⁸, Alexis Ogdie⁸, Daniel K. White¹⁰, Tuhina Neogi¹¹, Carla Scanzello¹² and Joshua Baker⁸, ¹University of Oklahoma, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Howard University Hospital and Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, ⁵Brown University, Philadelphia, PA, ⁶Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁷VA Puget Sound Health Care System, Seattle, WA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Washington VA Medical Center, Washington, District of Columbia, ¹⁰University of Delaware, Newark, DE, ¹¹Boston University School of Medicine, Boston, MA, ¹²University of Pennsylvania, Philadelphia
Background/Purpose: Intra-articular (IA) corticosteroid injections are commonly utilized for pain management in knee osteoarthritis (KOA). However, clinical characteristics associated with a greater benefit from corticosteroid…
Abstract Number: 2625 • ACR Convergence 2025
Early Detection of Knee Osteoarthritis – The Role of a Composite Disease Activity Metric: Data from the Osteoarthritis Initiative
Julieann Patarini¹, Timothy McAlindon², Jonggyu Baek¹, Emily Kirillov³, Nhung Vo³, Michael Richard³, Ming Zhang⁴, Matthew Harkey⁵, Grace Lo⁶, Shao-Hsien Liu¹, Kate Lapane¹, Charles Eaton⁷, James Mackay⁸ and Jeffrey Driban⁹, ¹UMass Chan Medical School, Worcester, MA, ²UMass Chan School of Medicine, Arlington, MA, ³Tufts Medical Center, Boston, MA, ⁴Boston University, Westford, MA, ⁵Michigan State University, East Lansing, MI, ⁶Baylor College of Medicine / MEDVAMC, Houston, TX, ⁷Brown University, Pawtucket, RI, ⁸University of Cambridge; Norwich Medical School, San Diego, CA, ⁹University of Massachusetts Chan Medical School, Marlborough, NH

Background/Purpose: Bone marrow lesions (BMLs) and effusion-synovitis are frequent and dynamic disease processes detected from early- to late-stage knee OA. These processes are associated with…
Abstract Number: 0314 • ACR Convergence 2025
What changes in quality of life can be observed in patients with knee or hip OA prior to total hip or total knee replacement surgery ? data from the KHOALA cohort
Anne-Christine Rat¹, LATOURTE Augustin², Maud Wieczorek³, Jérémie sellam⁴, willy Ngueyon Sime⁵, Jacques Pouchot⁶, Christian Roux⁷, Alain SARAUX⁸, Francis Guillemin⁹ and Joel Coste¹⁰, ¹Caen University hospital, UMR ¹⁰⁷⁵ Caen normandy university, Caen, France, ²Rheumatology Department, Lariboisiere Hospital, Paris, France, ³Lausanne Univserty, Lausanne, Switzerland, ⁴Saint-Antoine hospital, Assistance Publique – Hôpitaux de Paris, Paris, France, Sorbonne University, Paris, France, ⁵CIC, Epidémiologie Clinique, CHRU-Nancy, Inserm, Université de Lorraine, Nancy, France, nNancy, France, ⁶HEGP hospital, Assistance Publique-Hopitaux de Paris,, Paris, France, ⁷CHU Nice, Nice, France, ⁸CHU Brest, Brest, France, ⁹CHU Nancy, Nancy, France, ¹⁰, Assistance Publique – Hôpitaux de Paris, Paris, France
Background/Purpose: Few studies have examined how the quality of life (QoL) evolves in patients with osteoarthritis (OA) before undergoing total hip or total knee replacement…
Abstract Number: 0330 • ACR Convergence 2025
Prevalence of Radiographic and Symptomatic Osteoarthritis, and Ultrasound Features at the Knee: The Johnston County Health Study
Maya Patel¹, Carolina Alvarez², Todd Schwartz³, Tessa Walker¹, Serena Savage-Guin¹, Jordan Renner¹, Jonathan Samuels⁴, Janice Lin⁵, Minna Kohler⁶, Catherine Bakewell⁷, Yvonne Golightly⁸ and Amanda Nelson¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴NYU Langone, Rye Brook, NY, ⁵Stanford University, Palo Alto, CA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: To report sex and BMI differences among ultrasound (US) features of knee osteoarthritis (KOA), patient-reported symptoms (Ksx), radiographic KOA (rKOA), and symptomatic KOA (sxKOA),…
Abstract Number: 0852 • ACR Convergence 2025
LEVI-04 Significantly Reduces Bone Marrow Lesions and Symptoms in Knee Osteoarthritis: Results from a Phase II RCT
Simon Westbrook¹, Ali Guermazi² and Philip Conaghan³, ¹Levicept Ltd, Sandwich, United Kingdom, ²Boston University, West Roxbury, MA, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Bone marrow lesions (BMLs), detectable on MRI as areas of ill-defined high signal intensity on fluid-sensitive sequences, are a common feature of osteoarthritis (OA),…
Abstract Number: 1781 • ACR Convergence 2025
Specific gut microbiome remodeling occurs after induction of OA via DMM surgery compared to sham surgery
Aleksander Szymczak¹, Cindy Miranda Brawner², Nicholas Hanebutt², Gabriella Dyson², Montana Barrett², Anna Rapp³, Carla Scanzello⁴ and Matlock Jeffries¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³University of Pennsylavnia, Philadelphia, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: The destabilization of the medial meniscus (DMM) model is widely used in murine OA research due to its reproducibility and ability to recapitulate key…
Abstract Number: 1802 • ACR Convergence 2025
Clearance Kinetics and Cartilage Retention of MM-II, a Dispersion of Large Empty Liposomes, in Rat Knees
Roni Wechsler and Rany Rotem, Moebius Medical, Tel Aviv, Israel
Background/Purpose: MM-II is a dispersion of large, empty multilamellar liposomes for intraarticular (IA) injection that reduced knee pain in osteoarthritic patients for up to 26…
Abstract Number: 2083 • ACR Convergence 2025
Evaluation of a Parent-Trial as a Run-In Period: Efficacy and Safety of Repeat Injections of Lorecivivint over Three Years
Christopher Swearingen¹ and Yusuf Yazici², ¹Biosplice Therapeutics, Inc, San Diego, CA, ²NYU Grossman School of Medicine, La Jolla, CA
Background/Purpose: Lorecivivint (LOR) is an intra-articular CLK/DYRK inhibitor in clinical development for the treatment of knee OA. A Phase 3 Trial, OA-11 (NCT03928184), assessed clinical…
Abstract Number: 2099 • ACR Convergence 2025
Incidence and Prevalence of Osteoarthritis in the United States Compared to Global Trends: Insights from the Global Burden of Disease Study (1990–2021)
Khadija Mohib¹, Rameez Qasim², Nicolas Barnechea Alvarado¹, ZAUHA FAWAD MEMON³ and Muhammad Asjad Saleem⁴, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³Peoples University of Medical and Health Sciences for Women, Tando Allahyar, Sindh, Pakistan, ⁴Indus Hospital Karachi, Karachi
Background/Purpose: Osteoarthritis (OA) is the most prevalent musculoskeletal condition, predominantly affecting individuals over the age of 55. According to the World Health Organization (WHO), OA…
Abstract Number: 2626 • ACR Convergence 2025
Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)
Yusuf Yazici¹ and Christopher Swearingen², ¹NYU Grossman School of Medicine, La Jolla, CA, ²Biosplice Therapeutics, Inc, San Diego, CA
Background/Purpose: Increased pain and decreased function are hallmarks of knee OA progression. Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways,…
Abstract Number: 0315 • ACR Convergence 2025
Cross-sectional analysis of association between erosive hand osteoarthritis and cardiovascular disease.
Avanika Mahajan¹, Caroyln Harvey², Andy Abril³ and Megan Sullivan⁴, ¹Mayo Clinic, Scottsdale, ²Mayo Clinic, Phoenix, AZ, ³Mayo Clinic Florida, Jacksonville, ⁴Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Erosive hand osteoarthritis (EHOA) is an inflammatory subtype of hand OA that causes subchondral bone erosion and cortical destruction, often resulting in debilitating symptoms.…
Abstract Number: 0331 • ACR Convergence 2025
Safety and Efficacy of Colchicine in Osteoarthritis: A Systematic Review and Meta-Analysis of 6,965 Patients
Mohamed Abdelsalam¹, Bassant Elaraby Elsayed Badwy², Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

Background/Purpose: Osteoarthritis (OA) is the most common joint disease, that leads to significant pain and affects quality of life, particularly in older adults. Current treatments…
Abstract Number: 0919 • ACR Convergence 2025
Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
Stefanie Kurth¹, Andre Tiaden¹, Edveena Hanser¹, Simone Häner¹, Stavros Giaglis¹, Florian Geier¹, Dominik Burri¹, Katarzyna Buczak¹, Ute Heider², Stefan Wild², Yves Acklin¹, Christian Egloff¹ and Diego Kyburz³, ¹University of Basel, Basel, Switzerland, ²Miltenyi Biotec, Bergisch-Gladbach, Germany, ³University Hospital Basel, Basel, Switzerland
Background/Purpose: Extracellular vesicles (EVs) are secreted by virtually all cells and are known to carry bioactive cargo including proteins, RNA, DNA and metabolites. Analysis of…

« Previous Page
1
…
5
6
7
8
9
…
71
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].